Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Karam Devi, Anjana Bali, Pankaj Bhatia, Nirmal Singh & Amteshwar Singh Jaggi. (2023) Exploring the ameliorative potential of Bacopa monnieri in acetic acid induced ulcerative colitis in mice. Natural Product Research 0:0, pages 1-6.
Read now
Read now
Homayoon Bashiri & Arezoo Bozorgomid. (2020) Protective Effect of Asacol in Combination with Pantoprazole in Ulcerative Colitis Patients Who Defecate Asacol Tablets Intactly: A Clinical Trial Study. Clinical and Experimental Gastroenterology 13, pages 47-51.
Read now
Read now
Articles from other publishers (15)
Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe & Mi-Jin Kim. (2023) Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study. Biomedicines 11:9, pages 2575.
Crossref
Crossref
T. Kucharzik, A. Dignass, R. Atreya, B. Bokemeyer, P. Esters, K. Herrlinger, K. Kannengiesser, P. Kienle, J. Langhorst, A. Lügering, S. Schreiber, A. Stallmach, J. Stein, A. Sturm, N. Teich & B. Siegmund. (2023) Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009. Zeitschrift für Gastroenterologie 61:08, pages 1046-1134.
Crossref
Crossref
Jiaxing Zhao, Bing Zhang, Qing Mao, Kunqi Ping, Peng Zhang, Fengwei Lin, Dan Liu, Yao Feng, Ming Sun, Yan Zhang, Qiu Hua Li, Tingjian Zhang, Yanhua Mou & Shaojie Wang. (2022) Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis. Journal of Medicinal Chemistry 65:6, pages 4926-4948.
Crossref
Crossref
Alvaro Hernández Martínez, Pilar Navajas Hernández, María del Mar Martín Rodríguez, Marta Lázaro Sáez, Raúl Olmedo Martín, Andrea Núñez Ortiz, Federico Argüelles Arias, María del Carmen Fernández Cano, Francisco Gallardo Sánchez, Sandra Marín Pedrosa, Javier González García & Juan María Vázquez Morón. (2022) Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Ted A. Spiewak & Anish Patel. (2022) User's guide to JAK inhibitors in inflammatory bowel disease. Current Research in Pharmacology and Drug Discovery 3, pages 100096.
Crossref
Crossref
María Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodríguez, Manuel Barreiro-de Acosta, Jesús Martínez-Cadilla, María T Arroyo, Noemí Manceñido, Mónica Sierra-Ausín, Isabel Vera-Mendoza, María José Casanova, Pilar Nos, Carlos González-Muñoza, Teresa Martínez, Maia Boscá-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llaó, María Dolores Martín-Arranz, Marta Piqueras, Laura Ramos, Gerard Surís, Fernando Bermejo, Ana Y Carbajo, Diego Casas-Deza, Agnes Fernández-Clotet, María J García, Daniel Ginard, Ana Gutiérrez-Casbas, Luis Hernández, Alfredo J Lucendo, Lucía Márquez, Olga Merino-Ochoa, Francisco J Rancel, Carlos Taxonera, Antonio López Sanromán, Saioa Rubio, Eugeni Domènech & Javier P Gisbert. (2021) Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. Journal of Crohn's and Colitis 15:1, pages 35-42.
Crossref
Crossref
Antonio López-Sanromán, Juan V. Esplugues & Eugeni Domènech. (2021) Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterología y Hepatología (English Edition) 44:1, pages 39-48.
Crossref
Crossref
Torsten Kucharzik, Axel U. Dignass, Raja Atreya, Bernd Bokemeyer, Philip Esters, Klaus Herrlinger, Klaus Kannengießer, Peter Kienle, Jost Langhorst, Andreas Lügering, Stefan Schreiber, Andreas Stallmach, Jürgen Stein, Andreas Sturm, Niels Teich & Britta Siegmund. (2020) Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Zeitschrift für Gastroenterologie 58:12, pages e241-e326.
Crossref
Crossref
Richa Chibbar & Alan C. Moss. (2020) Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterology Clinics of North America 49:4, pages 689-704.
Crossref
Crossref
Antonio López-Sanromán, Juan V. Esplugues & Eugeni Domènech. (2020) Farmacología y seguridad de tofacitinib en colitis ulcerosa. Gastroenterología y Hepatología.
Crossref
Crossref
Rahel EhrenbergJenny GriffithCindy TheigsBryan McDonald. (2020) Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease. Journal of Managed Care & Specialty Pharmacy 26:6, pages 758-765.
Crossref
Crossref
Julián Panés & Javier P. Gisbert. (2019) Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 42:6, pages 403-412.
Crossref
Crossref
Julián Panés & Javier P. Gisbert. (2019) Efficacy of tofacitinib treatment in ulcerative colitis. Gastroenterología y Hepatología (English Edition) 42:6, pages 403-412.
Crossref
Crossref
P. Sehgal, J.‐F. Colombel, A. Aboubakr & N. Narula. (2018) Systematic review: safety of mesalazine in ulcerative colitis. Alimentary Pharmacology & Therapeutics 47:12, pages 1597-1609.
Crossref
Crossref
Alicia Algaba, Iván Guerra, Ana García García de Paredes, María Hernández Tejero, Carlos Ferre, Daniel Bonillo, Lara Aguilera, Antonio López-Sanromán & Fernando Bermejo. (2016) What is the real-life maintenance mesalazine dose in ulcerative colitis?. Revista Española de Enfermedades Digestivas 109.
Crossref
Crossref